👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Perrigo shares dip, breaking three-day gain streak

EditorHari Govind
Published 06/12/2023, 04:40
© Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect
US500
-
DJI
-
JNJ
-
ABT
-
PG
-
PRGO
-

NEW YORK - Perrigo Co . (NYSE:PRGO) saw its shares decline by 1.43% to close at $30.91 on Tuesday, halting a three-day run of advances. The pharmaceutical company's stock is currently below its August high by $9.37 when it reached $40.28.

The broader market experienced modest losses during the same session, with both the S&P 500 and Dow Jones Industrial Average recording slight declines. In tandem with the general market trend, other healthcare giants including Johnson & Johnson (NYSE:JNJ (NYSE:JNJ)), Procter & Gamble (NYSE:PG), and Abbott Laboratories (NYSE:NYSE:ABT) also witnessed their stock prices fall on Tuesday.

Perrigo's trading activity was notably subdued, with only 1.1 million shares changing hands compared to its average volume of around 1.6 million. The lower trading volume accompanied the stock's price drop, reflecting a quieter day on the market for Perrigo amid an overall downturn in the sector.

InvestingPro Insights

As Perrigo Co. navigates the market's fluctuations, InvestingPro data provides a deeper look into the company's financial health and performance. With a market capitalization of approximately $4.19 billion, Perrigo's valuation metrics show a negative P/E ratio of -21.91 for the last twelve months as of Q3 2023, indicating challenges in profitability. However, the company's revenue has seen a growth of 5.74% during the same period, suggesting some underlying strengths in its business operations.

InvestingPro Tips highlight that Perrigo has a commendable track record of raising its dividend for 21 consecutive years, underscoring its commitment to shareholder returns. Moreover, analysts predict that the company will be profitable this year, which could signal a turnaround from the current negative earnings multiple. Nevertheless, it's important to note that two analysts have revised their earnings estimates downwards for the upcoming period, which investors should consider as they assess the company's outlook.

For those interested in a comprehensive analysis of Perrigo and other healthcare giants, InvestingPro offers additional tips and insights. Currently, there are 9 more InvestingPro Tips available for Perrigo, which can be accessed by subscribing to InvestingPro. With a special Cyber Monday sale, new subscribers can enjoy a discount of up to 60%, and by using the coupon code sfy23, an additional 10% off a 2-year InvestingPro+ subscription can be claimed. These tips and data points could be crucial for investors looking to make informed decisions in a volatile market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.